Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SynOV1.1 in AFP positive solid tumors
NCT04612504Phase 1Unknown
- Sponsor
- Beijing SyngenTech Co., Ltd.
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SynOV1.1 in hepatocellular carcinoma (HCC), sponsored by Beijing SyngenTech Co., Ltd. Primary endpoints: Dose-Limiting Toxicities at 30 months, Maximum Tolerated Dose at 30 months and 1 more. Status: unknown.
02
Drugs
SynOV1.1
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04612504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04612504.